Ischemic heart diseases with PCI
Conditions
Interventions
Sponsors
Kurume University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients at least 20 years old (2) Patients who give written consent (3) Patients who are diagnosed as ACS and planned to undergo PCI or patients who are diagnosed as coronary heart disease and planned to undergo elective stent treatment in coronary artery
Exclusion criteria
Exclusion criteria: (1) Patients with tendency or factor of bleeding (2) Patients with severe hepatic dysfunction (3) Patients with severe renal dysfunction (4) Patients under antihypertensive therapy or with poor control of blood pressure (5) Patients with a history of cerebral infarction or transient cerebral ischemia (6) Patients with hypersensitivity to thienopyridine (7) Patients receiving thienopyridine within 30 days of the initial dose (8) Patients who have difficulties in participation in this study by the investigator's judgment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PRU value at 6 weeks after the initial dose | — |
Secondary
| Measure | Time frame |
|---|---|
| PRU value by genetic polymorphism of the CYP2C19 gene Frequency of hemorrhagic adverse events during the dosing period | — |
Countries
Japan
Contacts
Public ContactTakafumi Ueno
Kurume University Hospital Center of Cardio-vascular Disease
Outcome results
None listed